₹ 31.82
NAV (Apr 09)
Sectoral / Thematic - Pharma And Healthcare funds provides inflation beating growth over the long term and is suitable for investment objectives with duration of 10-15 years or longer (minimum 5 years).
The pharma benchmark index itself has been a material underperformer over an extended time frame.
Contrary to common perception, this category is also characterised by higher volatility.Investing in these funds will require investors to have a unique insight into the specific areas of investment that these funds focus on.In addition the investor will need to have the ability,inclination and expertise to monitor the prospects closely.Investors are therefore better off investing in diversified funds rather than this category.
Investment Duration5 years
7,32,612
Total Investment5,80,459
Wealth Gained13,13,071
Total Corpus Created (₹)
With CAGR of 22.779 % in 5 years₹ 31.818
NAV (Apr 9)
Last 1Y | 9.2% |
Last 3Y | 18.2% |
Last 5Y | 22.8% |
Last 10Y | - |
Since Inception | 13.3% |
6 Month CAGR | -12.4% |
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Expense Ratio | 0.74 % |
Launched 9Y ago | 2015-12-28 |
AUM in Crores | 1183.7 |
ISIN | INF277K019A3 |
Lock-in (days) | No Lock-in |
Benchmark | NIFTY Pharma Total Return Index |
SIP Minimum | 1000 |
Lumpsum Min. | 5000 |
Standard Deviation | 16.6 |
Beta | 1 |
Sharpe Ratio | 0.8 |
of
for
with step up of
Asset | Returns | Total Corpus | Gains | CAGR |
---|---|---|---|---|
Tata India Pharma & Healthcare Fund Direct (G) | 13,13,071 | 5,80,459 | 22.8% | |
EPF | 9,00,761 | 1,68,149 | 8.50% | |
Property | 8,67,662 | 1,35,050 | 7.00% | |
PPF | 8,69,819 | 1,37,207 | 7.10% | |
Bank FD | 8,46,471 | 1,13,859 | 6.00% | |
Gold | 8,46,471 | 1,13,859 | 6.00% | |
Savings Bank | 8,25,950 | 93,338 | 5.00% |
Disclaimer: Products compared like fixed deposits may provide fixed guaranteed returns. Mutual Funds investments are subject to market risk, read all scheme related documents carefully before investing. Past performance is not an indicator of future returns.
Sun Pharmaceutical Industries Ltd.
13.1%Aurobindo Pharma Ltd.
10.06%Lupin Ltd.
9.24%Dr. Reddy's Laboratories Ltd.
6.88%Cipla Ltd.
6.07%Healthcare
94.45%Services
2.39%Chemicals
1.21%Fund Name | Fund Size | |
---|---|---|
₹ 49,131 cr | ||
₹ 93,440 cr | ||
₹ 64,962 cr | ||
₹ 16,217 cr | ||
₹ 27,730 cr |
Tata Mutual Fund
Fund Name | Scripbox Opinion | Till Date CAGR | |
---|---|---|---|
6.3% | 5.1% | ||
7.4% | 6.8% | ||
7% | 7.1% | ||
19.1% | 23.4% | ||
11.7% | 16.3% |
Investment Duration5 years
7,32,612
Total Investment5,80,459
Wealth Gained13,13,071
Total Corpus Created (₹)
With CAGR of 22.779 % in 5 yearsWhat is the expense ratio for Tata India Pharma & Healthcare Fund Direct Plan Growth?
What is the current AUM of Tata India Pharma & Healthcare Fund Direct Growth?
What is the latest NAV of Tata India Pharma & Healthcare Fund Direct Growth?
What is the Riskometer rating for Tata India Pharma & Healthcare Fund Direct Plan Growth?
Which are the top sector holdings in Tata India Pharma & Healthcare Fund Direct Plan?
Which are the top stock holdings in Tata India Pharma & Healthcare Fund Direct Plan?
What is the asset allocation of Tata India Pharma & Healthcare Fund Direct Plan Growth?
What has been the performance of Tata India Pharma & Healthcare Fund Direct Growth returns?
Does Tata India Pharma & Healthcare Fund Direct Growth have a lock-in period?
Can I invest in both SIP and lump sum options in Tata India Pharma & Healthcare Fund Direct Plan Growth?
How to invest in Tata India Pharma & Healthcare Fund Direct Growth?
How can I redeem my investment in Tata India Pharma & Healthcare Fund Direct Plan?